Is CareDx, Inc. (NASDAQ:CDNA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating CareDx, Inc. at current levels.
Medicare reimbursement is back, growth is compounding at 39%, and the transplant monitoring monopoly is finally printing free cash flow.
Where CDNA is headed
CareDx in 2028 looks like a different company than the one that nearly died in 2023 when Medicare's MolDx program pulled coverage for surveillance testing of stable transplant patients. The reimbursement crisis is resolved, AlloSure and AlloMap are back in the standard of care, and management has rebuilt the testing services business while bolting on a software and digital health arm that gives them sticky workflow integration inside transplant centers. Revenue running at $470M+ with mid-teens organic growth, gross margins north of 70%, and operating margins finally crossing into the high single digits as the fixed-cost lab base scales. Free cash flow of $100M+ on a $1.1B market cap is the kind of math that gets a small-cap diagnostics company acquired or re-rated, not ignored.
Read the full Compass Direction on CDNA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $22.75).
See the full CDNA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is CareDx, Inc. (NASDAQ:CDNA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating CareDx, Inc. at current levels. Medicare reimbursement is back, growth is compounding at 39%, and the transplant monitoring monopoly is finally printing free cash flow.
What is CDNA's Compass Score?
CareDx, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for CDNA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the CDNA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.